Quick Hits

Significant advances in antiviral therapy with direct acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment over the past four years (Table). We have achieved nearly every characteristic of an ideal regimen: pangenotypic, excellent safety and tolerability, high sustained virologic response (SVR), low pill burden, simplified dosing schedule, short treatment duration, and high genetic […]

Quick Hits

Chronic hepatitis C infection (HCV) is a major public health problem affecting more than 71 million patients worldwide including more than 3.5 million patients in the United States.1 With the introduction of direct acting antiviral agents (DAAs), it is now possible to cure hepatitis C infection even in patients with advanced fibrosis, cirrhosis and HCV […]

Quick Hits

The advent of direct acting antivirals (DAAs) in the treatment of chronic hepatitis C infection has been revolutionary in that they have drastically mitigated the side effects of therapy while enhancing efficacy relative to interferon-based therapy. DAAs are broadly categorized into the NS3/4A protease inhibitors, NS5A inhibitors, and the non-nucleoside and nucleotide NS5B inhibitors. Ribavirin, […]

Quick Hits

The availability of highly efficacious and tolerable all-oral direct acting antiviral (DAA) regimens for the treatment of chronic hepatitis C virus (HCV) infection in 2014 was met with a mix of joy and relief among both HCV providers and chronically infected patients. Finally we could do away with the low cure rates and toxicities associated […]

Quick Hits

The prevalence of hepatitis C (HCV) in dialysis patients is higher than that of the general population, ranging from 1.8 to 8 percent in developed countries, with much higher rates in the developing world. Its prevalence correlates with the number of patient-years on dialysis. HCVinfected patients on maintenance dialysis experience increased mortality compared to uninfected […]